Form 4: Disc Medicine CFO Receives Equity Grants

Disc Medicine, Inc.'s Chief Financial Officer, Jean M. Franchi, was granted 19,000 restricted stock units and options to purchase 25,500 shares of common stock.

Summary

• Jean M. Franchi, Chief Financial Officer of Disc Medicine, Inc. (IRON), received equity grants.
• Granted 19,000 Restricted Stock Units (RSUs) on February 10, 2026, each representing a contingent right to receive one share of the Issuer's Common Stock.
• The RSUs will vest annually in four 25% installments, commencing on February 15, 2027, subject to Ms. Franchi's continued service.
• Granted options to purchase 25,500 shares of common stock on February 10, 2026, with an exercise price of $74.75 per share.
• These stock options will vest in 48 equal monthly installments, commencing on March 10, 2026, subject to Ms. Franchi's continued service.
• Following these transactions, Ms. Franchi beneficially owns 82,499 shares of common stock and 25,500 derivative securities (stock options).

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development, reflecting standard executive compensation practices aimed at retaining key talent and aligning management incentives with shareholder value creation.

Positives

• The equity grants incentivize the Chief Financial Officer, Jean M. Franchi, to remain with Disc Medicine and contribute to its long-term success.
• Equity compensation aligns the financial interests of the CFO with those of shareholders, promoting shared goals.
• The multi-year vesting schedules for both RSUs and stock options are designed to promote long-term commitment and retention of key executive talent.

Future Outlook

The vesting schedules for both the restricted stock units and stock options extend several years into the future, indicating an expectation of continued service from the Chief Financial Officer, Jean M. Franchi, and a long-term incentive structure designed to align her performance with the company's sustained growth.

Industry Context

StockSavvy.ai notes that the granting of restricted stock units and stock options is a standard practice in the biotechnology and pharmaceutical industry for executive compensation. This approach is widely used to attract, retain, and motivate key management personnel by aligning their financial interests with the long-term performance of the company.

Comparison to Industry Standards

• StockSavvy.ai observes that the structure of these equity grants, involving both RSUs and stock options with multi-year vesting schedules, is consistent with compensation practices seen at comparable biotech firms such as Moderna (MRNA) or BioNTech (BNTX) for their executive teams.
• The vesting periods (four years for RSUs, four years for options) are typical for executive retention programs in the sector, aiming to ensure sustained leadership and performance.
• The exercise price of $74.75 for the stock options reflects the market price at the time of grant, a common practice to incentivize future stock price appreciation.

Related Party Transactions

• Grant of 19,000 Restricted Stock Units to Chief Financial Officer Jean M. Franchi.
• Grant of options to purchase 25,500 shares of common stock to Chief Financial Officer Jean M. Franchi.

Stakeholder Impact

• Shareholders: Potential positive impact through incentivized management focused on long-term company performance and value creation.
• Employees: May signal stability in executive leadership and a commitment to retaining key personnel.

Next Steps

• Continued service by Jean M. Franchi to meet vesting conditions for the granted RSUs and stock options.
• Future vesting events for RSUs commencing February 15, 2027, and for stock options commencing March 10, 2026.

Key Dates

Keywords

Disc Medicine, IRON, Form 4, SEC filing, insider transaction, restricted stock units, RSUs, stock options, equity compensation, executive compensation, Jean M. Franchi, Chief Financial Officer